Therapeutic compounds
The invention provides a compound of formula I: wherein R 1 -R 6 , X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of MAO-B enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.
1. A compound selected from the group consisting of
2. The compound of claim 1 , wherein said compound is racemic.
3. The compound of claim 1 , wherein said compound is optically pure.
4. A compound of formula I:
wherein:
R 1 is (C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, or phenyl, each of which may be unsubstituted or substituted with one or more R e ;
one of R 2 and R 3 is absent and the other is hydrogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, amino(C 2 -C 6 )alkyl, or aryl, each of which may be unsubstituted or substituted with one or more groups selected from alkyl, halo, haloalkyl or nitro, Het, (C 3 -C 8 )cycloalkyl(C 1 -C 6 )alkyl, aryl(C 1 -C 6 )alkyl, (C 1 -C 6 ) or Het(C 1 -C 6 )alkyl;
X is —C(═O);
Y is piperidine;
n is an integer from 0 to 10 inclusive;
each of the n instances of R d is independently halo, hydroxy, cyano, nitro, azido, amino, (C 1 -C 6 )alkylamino, amino(C 1 -C 6 )alkyl, amido, (C 1 -C 6 )alkylamido, aryl amido, carboxylic acid, (C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkoxycarbonyl, carboxy, (C 1 -C 6 )alkanoyloxy, halo(C 1 -C 6 )alkenyl, Het, aryl, Het(C 1 -C 6 )alkyl, or aryl(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylaryl, sulfonyl, sulfonamido, urea, carbamate, unsubstituted or substituted with one or more R e , or two R d come together with the atom to which they are attached to form a ketone or spirocyclic carbocyclic or heterocyclic ring, or two R d come together with the atoms to which they are attached to form a bicyclic carbocyclic or heterocyclic ring, wherein each spirocyclic or bicyclic ring is unsubstituted or substituted with one or more halo, hydroxy, cyano, nitro, azido, (C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, halo (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkoxycarbonyl, carboxy, (C 1 -C 6 )alkanoyloxy, NR f R g , R f R g NC(═O)—, phenyl, or phenyl(C 1 -C 6 )alkyl, sulfonyl, sulfonamido, urea, carbamate, wherein R f and R g together with the nitrogen to which they are attached form a piperidine, pyrrolidine, morpholine, or thiomorpholine ring, unsubstituted or substituted with one or more R e ;
each R e is independently selected from halo, hydroxy, cyano, nitro, azido, (C 1 -C 6 )alkyl, Het, aryl, (C 1 -C 6 )alkylHet, (C 1 -C 6 )alkylaryl, (C 1 -C 6 )alkylHet(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylaryl(C 1 -C 6 )alkyl, (C 1 -C 6 )haloalkyl, (C 1 -C 6 )alkoxy, (C 1 -C 6 )haloalkoxy, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkoxycarbonyl, carboxy, and (C 1 -C 6 )alkanoyloxy;
R 5 is H, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkenyl, (C 1 -C 6 )alkynyl, aryl(C 1 -C 6 )alkyl;
R 6 is H, (C 1 -C 6 )alkyl, amino, amido, keto, or aryl(C 1 -C 6 )alkyl;
with the following proviso:
when X is CO═R 1 is CF 3 , R 3 is CH 3 , and Y is disubstituted at the 4-position wherein one of the substituents at the 4-position is phenyl, the other substituent at the 4-position of Y may not be (C═O)(C 1 -C 4 )alkyl;
or a pharmaceutically acceptable salt thereof.